Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery

Hatoum, Ida J.; Blackstone, Robin P.; Hunter, Tina D.; Francis, D.; Steinbuch, Michael; Harris, Jason L.; Kaplan, Lee M.

doi:10.1001/jamasurg.2015.3231

Cited by 52 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study is limited by the small sample size, intermediate duration of follow-up, heterogeneous population (both insulin and oral hypoglycemic agents), and few cardiovascular events. Participants in our study had relatively long duration of diabetes, high use of insulin, and high HbA 1c at study entrydall consistent with lower likelihood of achieving remission after metabolic surgery (22,32).…”

Section: Discussionsupporting

confidence: 52%

Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 52%

Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the 3‐year report of LAbariatric surgery‐2 (Longitudinal Assessment of Bariatric Surgery 2), rates of remission of hypertension and dyslipidaemia were 38 and 62 per cent respectively after gastric bypass; these are in accordance with the present results, which showed a lower rate of discontinuation of antihypertensive treatment compared with lipid‐lowering treatment. Only two studies have provided data on remission of hypertension and dyslipidaemia, based on pharmaceutical reimbursements recorded in administrative databases. Hatoum and co‐workers reported 18‐month remission rates of 60 and 69 per cent for hypertension and dyslipidaemia respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Only two studies have provided data on remission of hypertension and dyslipidaemia, based on pharmaceutical reimbursements recorded in administrative databases. Hatoum and co‐workers reported 18‐month remission rates of 60 and 69 per cent for hypertension and dyslipidaemia respectively.…”

Section: Discussionmentioning

confidence: 99%

Multicentre cohort study of antihypertensive and lipid-lowering therapy cessation after bariatric surgery

Thereaux

Lesuffleur

Czernichow

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

Background Few studies have assessed changes in antihypertensive and lipid‐lowering therapy after bariatric surgery. The aim of this study was to assess the 6‐year rates of continuation, discontinuation or initiation of antihypertensive and lipid‐lowering therapy after bariatric surgery compared with those in a matched control group of obese patients. Methods This nationwide observational population‐based cohort study used data extracted from the French national health insurance database. All patients undergoing gastric bypass or sleeve gastrectomy in France in 2009 were matched with control patients. Mixed‐effect logistic regression models were used to analyse factors that influenced discontinuation or initiation of treatment over a 6‐year interval. Results In 2009, 8199 patients underwent primary gastric bypass (55·2 per cent) or sleeve gastrectomy (44·8 per cent). After 6 years, the proportion of patients receiving antihypertensive and lipid‐lowering therapy had decreased more in the bariatric group than in the control group (antihypertensives: –40·7 versus –11·7 per cent respectively; lipid‐lowering therapy: –53·6 versus –20·2 per cent; both P < 0·001). Gastric bypass was the main predictive factor for discontinuation of therapy for hypertension (odds ratio (OR) 9·07, 95 per cent c.i. 7·72 to 10·65) and hyperlipidaemia (OR 11·91, 9·65 to 14·71). The proportion of patients not receiving treatment at baseline who were subsequently started on medication was lower after bariatric surgery than in controls for hypertension (5·6 versus 15·8 per cent respectively; P < 0·001) and hyperlipidaemia (2·2 versus 9·1 per cent; P < 0·001). Gastric bypass was the main protective factor for antihypertensives (OR 0·22, 0·18 to 0·26) and lipid‐lowering medication (OR 0·12, 0·09 to 0·15). Conclusion Bariatric surgery is associated with a good discontinuation of antihypertensive and lipid‐lowering therapy, with gastric bypass being more effective than sleeve gastrectomy.

show abstract

“…Their use has been rarer in obesity research but could potentially be very valuable in enhancing predictive accuracy when model forms and inter‐connections between variables may be non‐linear or unknown. For example, neural networks enhanced the capacity to predict long‐term success from preoperative data in bariatric surgery patients substantially over linear and logistic regression . Neural networks may have similar potential to amplify predictions of long‐term weight loss success during lifestyle interventions and long‐term behavioural adherence to physical activity.…”

Section: Predictive Machine Learning Algorithmsmentioning

confidence: 99%

A review of machine learning in obesity

et al. 2018

View full text Add to dashboard Cite

Rich sources of obesity-related data arising from sensors, smartphone apps, electronic medical health records and insurance data can bring new insights for understanding, preventing and treating obesity. For such large datasets, machine learning provides sophisticated and elegant tools to describe, classify and predict obesity-related risks and outcomes. Here, we review machine learning methods that predict and/or classify such as linear and logistic regression, artificial neural networks, deep learning and decision tree analysis. We also review methods that describe and characterize data such as cluster analysis, principal component analysis, network science and topological data analysis. We introduce each method with a high-level overview followed by examples of successful applications. The algorithms were then applied to National Health and Nutrition Examination Survey to demonstrate methodology, utility and outcomes. The strengths and limitations of each method were also evaluated. This summary of machine learning algorithms provides a unique overview of the state of data analysis applied specifically to obesity.

show abstract

Clinical Factors Associated With Remission of Obesity-Related Comorbidities After Bariatric Surgery

Cited by 52 publications

References 38 publications

Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study

Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study

Multicentre cohort study of antihypertensive and lipid-lowering therapy cessation after bariatric surgery

A review of machine learning in obesity

Contact Info

Product

Resources

About